Atrial Fibrillation – Landscape & Forecast – Disease Landscape & Forecast
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, direct-acting oral anticoagulants [DOACs]). Novel agents being investigated in clinical trials to treat AF include Anthos Therapeutics’ abelacimab, Bayer’s asundexian, Janssen’s milvexian, and ARCA’s bucindolol. We expect some of these drugs to launch during our forecast period and fulfill some of the unmet needs that remain in AF. Unmet needs include superior efficacy and safety / tolerability of antiarrythmic drugs, as bradycardia is an important safety concern in AF patients, and superior safety of anticoagulant drugs for stroke prevention in AF.
Questions answered
- What do key opinion leaders think about emerging therapies such as Anthos Therapeutics’ abelacimab, Bayer’s asundexian, Janssen’s milvexian, and ARCA’s bucindolol? How will emerging therapies differentiate themselves in an increasingly crowded market?
- What are the key treatment drivers and goals within AF? How do current therapies perform on these goals?
- What are the key unmet needs in AF, and how likely are they to be met?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Atrial Fibrillation - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for atrial fibrillation?
- What factors are constraining the market for atrial fibrillation?
- Annual atrial fibrillation sales by drug class in the major pharmaceutical markets: 2022-2032
- Annual atrial fibrillation sales by segment in the major pharmaceutical markets: 2022-2032
- Drug-type-specific trends
- Forecast
- Etiology and Pathophysiology
- Disease overview
- Etiology
- Major clinical manifestations and diagnosis of atrial fibrillation
- Classification of atrial fibrillation and disease progression
- Pathophysiology
- Factors contributing to atrial fibrillation
- Electrical remodeling
- Structural remodeling
- Contractile remodeling
- Neural / autonomic remodeling
- Role of inflammation in atrial fibrillation
- Role of genetics in atrial fibrillation
- Key pathways and drug targets
- Disease overview
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for atrial fibrillation
- Current treatments used for atrial fibrillation
- Market events impacting the use of key current therapies for atrial fibrillation
- Vitamin K antagonists
- Direct thrombin inhibitors
- Oral direct FXa inhibitors
- Beta blockers
- Non-dihydropyridine calcium channel blockers
- Digitalis glycosides
- Antiarrhythmics
- Antiplatelet therapies
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.